🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

CENTA raises Rs 20 Cr in Series A1 round led by Colossa Ventures

EntrackrEntrackr · 3m ago
CENTA raises Rs 20 Cr in Series A1 round led by Colossa Ventures
Medial

CENTA raises Rs 20 Cr in Series A1 round led by Colossa Ventures Centre for Teacher Accreditation (CENTA) has raised Rs 20 crore ($2.33 million) in its Series A1 round led by Colossa Ventures, with participation from existing investor Discovery Assets and angel investors. The proceeds will be used to grow in India and other markets and to improve its technology systems. Started by Ramya Venkataraman and Priyanka Arya, CENTA provides teacher certification, upskilling, and teacher-as-a-service (TAAS), connecting teachers with full-time and part-time jobs. The platform claims to have 1.7 million teachers from over 100 countries and 100,000 schools. While India is its largest market, CENTA also has users in the UAE, Nigeria, the Philippines, Bangladesh, and Ghana. It is forming ties in the UK and US. CENTA runs the International Teaching Professional’s Olympiad and has received awards from Dun & Bradstreet, NITI Aayog, UNESCO, and others.

1

Related News

Colossa WomenFirst Fund raises Rs 100 Cr in first close

EntrackrEntrackr · 1y ago
Colossa WomenFirst Fund raises Rs 100 Cr in first close
Medial

Colossa Ventures, a SEBI-registered independent venture capital management company, has announced the first close of its maiden fund – Colossa WomenFirst Fund at Rs 100 crore. The fund with a target corpus of Rs 500 crore will primarily focus on investing in the pre-Series A stage and beyond. Based on research Colossa aims to create a niche in healthcare & healthtech, fintech, climate & cleantech, deeptech and the consumer sectors. The fund’s strategy is to leverage gender-diversity to generate alpha, and has attracted institutions such as SIDBI and family offices like Dr. Ranjan Pai’s Family Office, and the Shriram Ownership Trust, among others to invest in the first close. Co-founded in 2022 by Ashu Suyansh and Vandana Rajadhyaksha, Colossa WomenFirst Fund is a sector-agnostic venture growth fund, that seeks to revolutionize the startup landscape by focusing exclusively on women-founded or co-founded, or where women are the main beneficiaries. A bunch of women-focused funds are currently active in India. For context, Kalaari Capital runs CXXO initiative for female founders. Gender-focused investment platform Achieving Women Equity (AWE) Funds also launched its maiden India fund amounting to Rs 350 crore. Search giant Google runs a program called Google for Startups Women Founders Fund and provides $100,000 in equity-free cash to female-founded startups. Saha Fund, She Capital, and StrongHer Ventures also focus on women founder-led startups.

Exclusive: Kiran Mazumdar Shaw’s Immuneel Therapeutics raises Rs 100 Cr

EntrackrEntrackr · 1y ago
Exclusive: Kiran Mazumdar Shaw’s Immuneel Therapeutics raises Rs 100 Cr
Medial

Cancer focused biotech startup Immuneel Therapeutics has raised Rs 100 crore or $12 million in the extension of Series A round from Taiba Middle East FZ LLC. This is the third round of investment for the Bengaluru-based company since its inception in 2018. The board at Immuneel Therapeutic has passed a special resolution to issue 1o equity shares and 8,164 Series A1 CCPS at an issue price of Rs 1,22,330 each to raise Rs 100 crore or $12 million, its regulatory filing accessed from the Registrar of Companies show. The company will use these investments for growth and expansion as decided by the board, the filings further added. As per TheKredible’s estimates, the firm has been valued at around Rs 587 crore or $71 million (post-allotment). Following the fresh proceeds, Taiba Middle East FZ holds a 17% stake in Immuneel Therapeutics. The round appears to be ongoing and it may raise more funds. The company has raised around $40 million to date including its $15 million Series A financing co-led by Eight Roads Ventures, True North, and F-Prime Capital in 2022. Founded by Biocon founder Kiran Mazumdar Shaw, oncologist and Pulitzer winner — Siddhartha Mukherjee and Kush Parwar, Immuneel Therapeutics is an Indian clinical-stage startup which is engaged in developing cell and gene therapies for cancer patients. It’s also working on developing its own pipeline of chimeric antigen receptor T-cell (CAR-T) therapies and other cellular immunotherapies for management and treatment of cancer. The firm claims to offer therapies at one-third of the costs borne for gene therapies in America. While the company is yet to file its annual statements for FY24, six-year-old Immuneel Therapeutics remained at a pre-revenue stage in FY23. Its losses stood at Rs 39 crore in the fiscal year ending March 2023.

Download the medial app to read full posts, comements and news.